Experimental and Clinical Endocrinology & Diabetes, Table of Contents Exp Clin Endocrinol Diabetes 2023; 131(01/02): 24-32DOI: 10.1055/a-1946-3728 German Diabetes Association: Clinical Practice Guidelines Diabetes Mellitus at an Elderly Age Andrej Zeyfang 1 Department of Internal Medicine, Geriatric Medicine, Palliative Medicine and Diabetology, medius Klinik Ostfildern-Ruit and Nürtingen, Germany , Jürgen Wernecke 2 Department of Geriatric Medicine, Agaplesion Diakonieklinikum Hamburg, Germany , Anke Bahrmann 3 Department of Cardiology, Angiology and Pneumology, University Hospital of Heidelberg, Germany › Author Affiliations Recommend Article Abstract Buy Article Full Text References References 1 Bahrmann A, Bahrmann P, Baumann J. et al. AWMF S2k-Leitlinie Diabetes im Alter, S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. Diabetologie 2018; 13: 423-489 2 Wernecke J, Bahrmann A, Zeyfang A. Individuelle Therapieziele bei betagten Diabetespatienten. Diabetologe 2012; 8: 108-112 3 Hodeck K, Tittel SR, Dreyhaupt I. et al. Charakteristika von Diabetespatienten mit und ohne Pflegebedürftigkeit. Diabetologie 2020; 15: 392-399 4 Budnitz DS, Lovegrove MC, Shehab N. et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365: 2002-2012 5 German Medical Association (Bundesärztekammer – BÄK), Associations of Statutory Health Insurance Physicians (Kassenärztliche Bundesvereinigung – KBV), Working Group of the Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften – AWMF). Nationale Versorgungsleitlinie Typ-2-Diabetes – Teilpublikation der Langfassung. 2021; 2. Auflage. Version 1 6 Lacy ME, Gilsanz P, Eng Ch. et al. Severe Hypoglycemia and Cognitive Function in Older Adults With Type 1 Diabetes: The Study of Longevity in Diabetes (SOLID). Diabetes Care 2019; 43: 541-548 7 Beckett NS, Peters R, Fletcher AE. et al. for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898 8 Bahrmann A, Wernecke J. Der geriatrische Patient mit diabetischem Fußsyndrom. Diabetologe 2022; 18: 225-231 9 Kansagara D, Fu R, Freeman M. et al. Intensive insulin therapy in hospitalized patients: a systematic review. Ann Intern Med 2011; 154: 268-282 10 Zeyfang A, Feucht I, Fetzer G. et al. Eine strukturierte geriatrische Diabetiker-Schulung (SGS) ist sinnvoll. Diabetes 2001; 10: 203-207 11 Wehling M, Burkhardt H. Hrsg. Arzneimitteltherapie für Ältere. 5. Aufl.. Heidelberg: Springer; 2019 12 Pfeffer MA, Claggett B, Diaz R. et al. for the ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373: 2247-2257 13 Marso SP, Daniels GH, Brown-Frandsen K. et al. for the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322 14 Marso SP, Bain SC, Consoli A. et al. for the SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834-1844 15 Holman RR, Bethel A, Mentz RJ. et al. for the EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377: 1228-1239 16 Gerstein HC, Colhoun HM, Dagenais GR. et al. Dulaglutide an cardiovascular outcomes in type 2 diabetes (REWIND). Lancet 2019; 394: 121-130 17 Zinman B, Wanner Ch, Lachin JM. et al. for the EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128 18 Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380: 2295-2306 19 Zeyfang A, Berndt S, Aurnhammer G. et al. A short easy test can detect ability for autonomous insulin injection by the elderly with diabetes mellitus. J Am Med Dir Assoc 2012; 13: 81.e15-81.e8.1E18 20 McMurray JJV, Solomon SD, Inzucchi SE. et al. for the DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381: 1995-2008 21 Rosenstock J, Dailey G, Massi-Benedetti M. et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28: 950-955 22 Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci 2007; 62: 722-727 23 Kulzer B, Albus C, Herpertz S et al. Psychosoziales und Diabetes – Teil 1. S2-Leitlinie Psychosoziales und Diabetes – Langfassung. Diabetologie 2013; 8: 198-242 und Teil 2. Diabetologie 2013: 8: 292–324 24 Cheng G, Huang C, Deng H. et al. Diabetes as a risk factor for dementia and mild cognitive im-pairment: a meta-analysis of longitudinal studies. Intern Med J 2012; 42: 484-491 25 Jackson SL, Scholes D, Boyko EJ. et al. Urinary incontinence and Diabetes in Postmeopausal Women. Diabetes Care 2005; 28: 1730-1738
